Overview
Allogeneic stem cell transplantation with a focus on the use of umbilical cord blood grafts; Allogenic stem cell transplantation for Sickle Cell Disease; Prevention of acute and chronic graft versus host disease; Improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation.
Current Appointments & Affiliations
Professor of Medicine
·
2016 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Affiliate of the Duke Regeneration Center
·
2021 - Present
Duke Regeneration Center,
Basic Science Departments
Recent Publications
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.
Journal Article Transplant Cell Ther · December 2025 Allogeneic hematopoietic cell transplantation (HCT) remains a curative therapy for many patients with hematologic malignancies, bone marrow failure syndromes, inborn errors of immunity and metabolic disorders. Current donor selection strategies typically p ... Full text Link to item CiteRisk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network Study.
Journal Article Transplantation · October 1, 2025 BACKGROUND: There is a growing population of hematopoietic cell transplantation (HCT) survivors who later require a solid organ transplant (SOT). However, there are limited data on survival, risk factors (RFs) for SOT graft loss, and death. METHODS: This i ... Full text Link to item CiteRisk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study.
Journal Article Transplantation · October 1, 2025 BACKGROUND: There is a growing population of solid organ transplant (SOT) survivors who subsequently require a hematopoietic cell transplant (HCT), although there are limited data on survival, risk factors for SOT graft loss, and death in this cohort. METH ... Full text Link to item CiteRecent Grants
Blood and Marrow Transplant Clinical Trials Network
Clinical TrialPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2001 - 2031Deciphera DCC-3014-02-001: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Clinical TrialPrincipal Investigator · Awarded by Deciphera Pharmaceuticals, LLC · 2025 - 2030A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030View All Grants
Education, Training & Certifications
Rush University ·
1992
M.D.